
Sanofi will pay Regeneron $582m in deal restructuring
pharmafile | January 7, 2019 | News story | Sales and Marketing |Â Â Deals, Regeneron, Sanofi, biotech, pharmaÂ
French pharmaceutical giant Sanofi will pay US biotech Regeneron $582 million, as part of a restructuring of an earlier deal between the two firms.
It is hoped that the new arrangement will offer Sanofi increased flexibility in advancing its early-stage immuno-oncology pipeline independently.
Meanwhile Regeneron will retain all rights to its other immuno-oncology discovery and development programmes.
Sanofi will pay Regeneron an initial sum of $462 million, which will cover Sanofi’s share of the costs for the immuno-oncology discovery programme for the last quarter of 2018, as agreed under the original terms of the deal set in 2015.
Sanofi will also pay an additional $120 million, which will cover other development costs for two selected clinical-stage bispecific antibodies, plus the termination fee for the other programs under the original immuno-oncology agreement. The original deal was scheduled to end in approximately mid-2020.
The agreement will secure Sanofi’s right to opt-in to the BCMAxCD3 and MUC16xCD3 bispecific programs when proof of concept is achieved or when the allocated funding is expended.
Louis Goss
Related Content

Regeneron announces presentations of new data on Eylea HD for retinal disease
Regeneron has presented data for Eylea HD (aflibercept) 8mg injection for retinal disease. The data …

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …

Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …





